Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1
Janssen seeks approval for investigational regimen that aims to combine efficacy, durability, and the high genetic barrier to resistance of darunavir with the renal and bone safety profile of emtricitabine/tenofovir alafenamide in a once daily pill
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Food and Drug Administration (FDA) | Genetics | New Drug Applications | Pharmaceuticals | Prezista | Truvada | Viread